Revisiting liver metabolism through acetyl-CoA carboxylase inhibition

被引：1

作者：

Perez-Diaz, Armando Jesus ^{[1
]}

Nunez-Sanchez, Maria Angeles ^{[2
]}

Ramos-Molina, Bruno ^{[2
]}

机构：

[1] Univ ROMA TRE, Dept Sci, I-00146 Rome, Italy

[2] Biomed Res Inst Murcia IMIB, Obes Diabet & Metab Lab, Murcia 30120, Spain

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2024年 / 35卷 / 07期

关键词：

NASH;

D O I：

10.1016/j.tem.2024.04.010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Liver-targeted acetyl-coenzyme A (CoA) carboxylase (ACC) inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD) trials reveal notable secondary effects: hypertriglyceridemia and altered glucose metabolism, paradoxically with reduced hepatic steatosis. In their study, Deja et al. explored how hepatic ACC influences metabolism using different pharmacological and genetic methods, coupled with targeted metabolomics and stable isotope-based tracing techniques.

引用

页码：563 / 565

页数：3

共 12 条

[1] From NASH to HCC: current concepts and future challenges
Anstee, Quentin M.
Reeves, Helen L.
Kotsiliti, Elena
Govaere, Olivier
Heikenwalder, Mathias
[J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (07) : 411 - 428
[2] Lipogenesis inhibitors: therapeutic opportunities and challenges
Batchuluun, Battsetseg
Pinkosky, Stephen L.
Steinberg, Gregory R.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (04) : 283 - 305
[3] Pharmacological Activation of Nrf2 Enhances Functional Liver Regeneration
Chan, Benjamin K. Y.
Elmasry, Mohamed
Forootan, Shiva S.
Russomanno, Giusy
Bunday, Tobias M.
Zhang, Fang
Brillant, Nathalie
Lewis, Philip J. Starkey
Aird, Rhona
Ricci, Emanuele
Andrews, Timothy D.
Sison-Young, Rowena L.
Schofield, Amy L.
Fang, Yongxiang
Lister, Adam
Sharkey, Jack W.
Poptani, Harish
Kitteringham, Neil R.
Forbes, Stuart J.
Malik, Hassan Z.
Fenwick, Stephen W.
Park, B. Kevin
Goldring, Christopher E.
Copple, Ian M.
[J]. HEPATOLOGY, 2021, 74 (02) : 973 - 986
[4] Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availability
Deja, Stanislaw
Fletcher, Justin A.
Kim, Chai-Wan
Kucejova, Blanka
Fu, Xiaorong
Mizerska, Monika
Villegas, Morgan
Pudelko-Malik, Natalia
Browder, Nicholas
Inigo-Vollmer, Melissa
Menezes, Cameron J.
Mishra, Prashant
Berglund, Eric D.
Browning, Jeffrey D.
Thyfault, John P.
Young, Jamey D.
Horton, Jay D.
Burgess, Shawn C.
[J]. CELL METABOLISM, 2024, 36 (05) : 1088 - 1104.e12
[5] Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents
Goedeke, Leigh
Bates, Jamie
Vatner, Daniel F.
Perry, Rachel J.
Wang, Ting
Ramirez, Ricardo
Li, Li
Ellis, Matthew W.
Zhang, Dongyan
Wong, Kari E.
Beysen, Carine
Cline, Gary W.
Ray, Adrian S.
Shulman, Gerald I.
[J]. HEPATOLOGY, 2018, 68 (06) : 2197 - 2211
[6] A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease
Hammoutene, Adel
Laouirem, Samira
Albuquerque, Miguel
Colnot, Nathalie
Brzustowski, Angelique
Valla, Dominique
Provost, Nicolas
Delerive, Philippe
Paradis, Valerie
[J]. JHEP REPORTS, 2023, 5 (10)
[7] Mechanisms and therapeutic implications of selective autophagy in nonalcoholic fatty liver disease
Jin, Suwei
Li, Yujia
Xia, Tianji
Liu, Yongguang
Zhang, Shanshan
Hu, Hongbo
Chang, Qi
Yan, Mingzhu
[J]. JOURNAL OF ADVANCED RESEARCH, 2025, 67 : 317 - 329
[8] Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation
Kim, Chai-Wan
Addy, Carol
Kusunoki, Jun
Anderson, Norma N.
Deja, Stanislaw
Fu, Xiaorong
Burgess, Shawn C.
Li, Cai
Chakravarthy, Manu
Previs, Steve
Milstein, Stuart
Fitzgerald, Kevin
Kelley, David E.
Horton, Jay D.
[J]. CELL METABOLISM, 2017, 26 (02) : 394 - +
[9] Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Kokkorakis, Michail
Boutari, Chrysoula
Hill, Michael A.
Kotsis, Vasilios
Loomba, Rohit
Sanyal, Arun J.
Mantzoros, Christos S.
[J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 154
[10] Intermittent fasting-the future treatment in NASH patients?
Minciuna, Iulia
Gallage, Suchira
Heikenwalder, Mathias
Zelber-Sagi, Shira
Dufour, Jean-Francois
[J]. HEPATOLOGY, 2023, 78 (04) : 1290 - 1305

← 1 2 →